ENHERTU Gets FDA Nod for High-Risk Early HER2+ Breast Cancer
October 1, 2025
If approved, ENHERTU followed by THP could represent a new treatment approach prior to surgery in this setting Daiichi Sankyo and AstraZeneca’s supplemental Biologics License